Miltenyi Biotec Sars-Cov-2 Antigen For Investigation of Virus-Specific Immune Responses; 100 µg

Miltenyi Biotec The receptor binding domain (RBD) locates C-terminally within the S1 subunits of the spike (S) protein. The S protein forms a homotrimeric structure on the surface of the SARS-CoV-2 virus and binds to the angiotensin-converting enzyme 2 (ACE2) receptor of target cells. Recent studies have shown that the predominant activated form displays one RBD rotated upwards into an ACE2-accessible state and it is known that binding of RBD to ACE2 is a major contributor for interaction of the S protein with its target receptor. | The SARS-CoV-2 mutant strain B.1.1.529, also known as Omicron variant, was first identified during the Covid-19 pandemic in Botswana/ South Africa in late November 2021. Due to increased transmissibility and substantial immune evasion it spread rapidly around the globe. | The BA.1 lineage is defined by 16 amino acid substitutions in the RBD (G339D, S371L, S373P, S375F, K417N (already known from B.1.351-Beta), N440K, G446S, S477N, T478K (already known from B.1.617.2-Delta), E484A, Q493R, G496S, Q498R, N501Y (already known from B.1.1.7-Alpha, B.1.351-Beta and P.1-Gamma), T547K, Y505H). | Preliminary evidence suggests an increased risk of reinfection with this variant, as compared to other VOCs. | The SARS-CoV-2 RBD B.1.1.529 (HEK) protein covers amino acids R319 to S591 of the spike protein and contains a C-terminal His-tag and a N-terminal AviTag. Recombinant SARS-CoV-2 RBD B.1.1.529 (HEK)-Biotin is specifically biotinylated at a single site, preserving full functionality of the RBD. | The receptor binding domain (RBD) locates C-terminally within the S1 subunits of the spike (S) protein. The S protein forms a homotrimeric structure on the surface of the SARS-CoV-2 virus and binds to the angiotensin-converting enzyme 2 (ACE2) receptor of target cells. Recent studies have shown that the predominant activated form displays one RBD rotated upwards into an ACE2-accessible state and it is known that binding of RBD to ACE2 is a major contributor for interaction of the S protein with its target receptor. | The SARS-CoV-2 mutant strain B.1.1.529, also known as Omicron variant, was first identified during the Covid-19 pandemic in Botswana/ South Africa in late November 2021. Due to increased transmissibility and substantial immune evasion it spread rapidly around the globe. | The BA.1 lineage is defined by 16 amino acid substitutions in the RBD (G339D, S371L, S373P, S375F, K417N (already known from B.1.351-Beta), N440K, G446S, S477N, T478K (already known from B.1.617.2-Delta), E484A, Q493R, G496S, Q498R, N501Y (already known from B.1.1.7-Alpha, B.1.351-Beta and P.1-Gamma), T547K, Y505H). | Preliminary evidence suggests an increased risk of reinfection with this variant, as compared to other VOCs. | The SARS-CoV-2 RBD B.1.1.529 (HEK) protein covers amino acids R319 to S591 of the spike protein and contains a C-terminal His-tag and a N-terminal AviTag. Recombinant SARS-CoV-2 RBD B.1.1.529 (HEK)-Biotin is specifically biotinylated at a single site, preserving full functionality of the RBD. | - MLTY (Additional S&H or Hazmat Fees May Apply)